Skip to main content

Joan Castell Conesa

Institutions of which they are part

Molecular Medical Imaging
Vall Hebron Institut de Recerca

Joan Castell Conesa

Institutions of which they are part

Molecular Medical Imaging
Vall Hebron Institut de Recerca

Projects

El test de apomorfina como marcador biológico de recaídas en pacientes dependientes de cocaína

IP: Miquel Casas Brugué
Collaborators: Joan Castell Conesa
Funding agency: Instituto de Salud Carlos III
Funding: 124355
Reference: PI051982
Duration: 01/01/2006 - 28/02/2009

Patologia Cardiocirculatòria

IP: -
Collaborators: Ignacio Ferreira González, José Antonio Barrabés Riu, Antonia Sambola Ayala, Angeles Rojas Lopez, Antonio Rodríguez Sinovas, Joan Castell Conesa, Artur Evangelista Masip, Elsa Nieto Santa, Teresa González Alujas, Lourdes Trobo Redondo, Enric Domingo Ribas, Jaume Sagristà Sauleda, Aida Ribera Sole, Santiago Aguade Bruix, Rosa María Lidón Corbi, Ignasi Barba Vert, Bruno García del Blanco, Pilar Tornos Mas, Elisabet Miro Casas, Marisol Ruiz Meana, Javier Inserte Igual
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 50600
Reference: 2005SGR 00985
Duration: 01/01/2006 - 31/12/2009

IM3. Imagen médica molecular y multimodalidad.

IP: Joan Castell Conesa
Collaborators: Gemma Cuberas Borros
Funding agency: Instituto de Salud Carlos III
Funding: 46449
Reference: G03/185
Duration: 01/01/2003 - 31/12/2005

Determinación de los valores de referencia de los volúmenes y fracción de eyección del ventrículo izquierdo mediante tomogammagrafia sincronizada en función de la edad y sexo

IP: -
Collaborators: Joan Castell Conesa, Santiago Aguade Bruix
Funding agency: Fundación Mapfre Medicina
Funding: 12020.24
Reference: MAPFRE_2001_01
Duration: 01/03/2003 - 01/03/2004

Related news

The event, organized by Vall d'Hebron and Eurecat, has brought together health professionals and researchers in clinically applied AI to improve the medical care of patients.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Phase IV AI is included in the Horizon Europe programme, lasts 3 years and prioritises data security and privacy compliance.

Related professionals

José Luis Peiró Ibáñez

José Luis Peiró Ibáñez

Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Nina Borràs Agustí

Nina Borràs Agustí

Postdoctoral researcher
Transfusional Medicine
Read more
Clàudia Faúndez Vidiella

Clàudia Faúndez Vidiella

Predoctoral researcher
Protein kinases in cancer research
Read more
Laura Soler Colomer

Laura Soler Colomer

Predoctoral researcher
Growth and Development
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.